Allison N. Lau

Allison N. Lau

Auto-generated profile, based on publicly available information

Allison N. Lau

Koch Institute for Integrative Cancer Research and the Department of Biology at Massachusetts Institute of Technology, Cambridge, MA 02139, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2013 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
MMMorvarid Mohseni
Morvarid Mohseni
JSJianlong Sun
Jianlong Sun
ALAllison Lau
Allison Lau
SCStephen Curtis
Stephen Curtis
JGJeffrey Goldsmith
Jeffrey Goldsmith
FCFernando D. Camargo
Fernando D. Camargo

1 May 2012 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
PDF file
KTKristen A. Tropea
Kristen A. Tropea
ELEva Leder
Eva Leder
MAMuhammad Aslam
Muhammad Aslam
ALAllison N. Lau
Allison N. Lau
DRDavid M. Raiser
David M. Raiser
CKCarla F. Kim
Carla F. Kim
Bronchopulmonary dysplasia (BPD) remains a major complication of prematurity resulting in significant morbidity and mortality. The pathology of BPD is multifactorial and leads to alveolar simplification and distal lung injury. Previous studies have shown a beneficial effect of systemic treatment with bone marrow-derived mesenchymal stromal cells (MSCs) and MSC-conditioned media (MSC-CM) leading to amelioration of the lung parenchymal and vascular injury in vivo in the hyperoxia murine model of BPD. It is possible that the beneficial response from the MSCs is at least in part due to activation of endogenous lung epithelial stem cells. Bronchioalveolar stem cells (BASCs) are an adult lung stem cell population capable of self-renewal and differentiation in culture, and BASCs proliferate in response to bronchiolar and alveolar lung injury in vivo. Systemic treatment of neonatal hyperoxia-exposed mice with MSCs or MSC-CM led to a significant increase in BASCs compared with untreated controls. Treatment of BASCs with MSC-CM in culture showed an increase in growth efficiency, indicating a direct effect of MSCs on BASCs. Lineage tracing data in bleomycin-treated adult mice showed that Clara cell secretory protein-expressing cells including BASCs are capable of contributing to alveolar repair after lung injury. MSCs and MSC-derived factors may stimulate BASCs to play a role in the repair of alveolar lung injury found in BPD and in the restoration of distal lung cell epithelia. This work highlights the potential important role of endogenous lung stem cells in the repair of chronic lung diseases.

1 July 2010 in Cell Stem Cell
Verified
Journal Article
Closed access
SCStephen J. Curtis
Stephen J. Curtis
KSKerstin W. Sinkevicius
Kerstin W. Sinkevicius
DLDanan Li
Danan Li
ALAllison N. Lau
Allison N. Lau
RRRebecca R. Roach
Rebecca R. Roach
CKCarla F. Kim
Carla F. Kim

30 June 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
KSKerstin W. Sinkevicius
Kerstin W. Sinkevicius
CKChristina Kriegel
Christina Kriegel
KBKelly J. Bellaria
Kelly J. Bellaria
JLJaewon Lee
Jaewon Lee
ALAllison N. Lau
Allison N. Lau
CKCarla F. Kim
Carla F. Kim
Significance: New effective therapies are desperately needed for lung cancer because most current lung cancer treatments rarely prevent the metastatic disease that causes the majority of patient deaths. We discovered that the neurotrophin receptor TrkB is an important therapeutic target in metastatic lung cancer using a combination of cell line assays, conditional mouse models, and patient samples.

1 June 2012 in Molecular Therapy
Verified
Journal Article
Open access
ALAllison N Lau
Allison N Lau
MGMeagan Goodwin
Meagan Goodwin
CKCarla F Kim
Carla F Kim
DWDaniel J. Weiss
Daniel J. Weiss
A number of novel approaches for repair and regeneration of injured lung have developed over the past several years. These include a better understanding of endogenous stem and progenitor cells in the lung that can function in reparative capacity as well as extensive exploration of the potential efficacy of administering exogenous stem or progenitor cells to function in lung repair. Recent advances in ex vivo lung engineering have also been increasingly applied to the lung. The current status of these approaches as well as initial clinical trials of cell therapies for lung diseases are reviewed below.

10 July 2020 in eLife
Verified
Journal Article
Open access
ALAllison N Lau
Allison N Lau
ZLZhaoqi Li
Zhaoqi Li
LDLaura V Danai
Laura V Danai
AWAnna M Westermark
Anna M Westermark
ADAlicia M Darnell
Alicia M Darnell
MHMatthew G Vander Heiden
Matthew G Vander Heiden
Tumors are composed of many different cell types including cancer cells, fibroblasts, and immune cells. Dissecting functional metabolic differences between cell types within a mixed population can be challenging due to the rapid turnover of metabolites relative to the time needed to isolate cells. To overcome this challenge, we traced isotope-labeled nutrients into macromolecules that turn over more slowly than metabolites. This approach was used to assess differences between cancer cell and fibroblast metabolism in murine pancreatic cancer organoid-fibroblast co-cultures and tumors. Pancreatic cancer cells exhibited increased pyruvate carboxylation relative to fibroblasts, and this flux depended on both pyruvate carboxylase and malic enzyme 1 activity. Consequently, expression of both enzymes in cancer cells was necessary for organoid and tumor growth, demonstrating that dissecting the metabolism of specific cell populations within heterogeneous systems can identify dependencies that may not be evident from studying isolated cells in culture or bulk tissue.